Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC42 | P60953 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449897 | 0.97 | CDC42 (0.53) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5456623 | 0.94 | CDC42 (0.55) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5445912 | 0.88 | CDC42 (0.52) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5455124 | 0.88 | GAA (0.53) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5453990 | 0.88 | GAA (0.55) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5445856 | 0.87 | CDC42 (0.48) | CDC42GAACASP6MAPTDHODH | |
| SCHEMBL5468183 | 0.85 | BRD3 (0.52) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5447195 | 0.85 | MAPT (0.50) | CDC42GAACASP6PRMT5MAPT | |
| SCHEMBL5460537 | 0.84 | CDC42 (0.49) | CDC42GAACASP6MAPTNPSR1 | |
| SCHEMBL5456608 | 0.84 | GAA (0.54) | CDC42GAACASP6PRMT5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | CDC42 1241/4885GAA 1417/4885CASP6 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.